Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of GoodwillAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harvard Bioscience (HBIO) Capital Expenditures (2016 - 2025)

Harvard Bioscience (HBIO) has disclosed Capital Expenditures for 16 consecutive years, with $207000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Capital Expenditures fell 76.48% to $207000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $1.1 million, a 65.02% decrease, with the full-year FY2024 number at $2.6 million, up 47.87% from a year prior.
  • Capital Expenditures was $207000.0 for Q3 2025 at Harvard Bioscience, up from $89000.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $880000.0 in Q3 2024 to a low of $89000.0 in Q2 2025.
  • A 5-year average of $422421.1 and a median of $442000.0 in 2022 define the central range for Capital Expenditures.
  • Peak YoY movement for Capital Expenditures: surged 459.38% in 2021, then plummeted 89.12% in 2025.
  • Harvard Bioscience's Capital Expenditures stood at $358000.0 in 2021, then plummeted by 34.36% to $235000.0 in 2022, then soared by 253.19% to $830000.0 in 2023, then crashed by 63.73% to $301000.0 in 2024, then tumbled by 31.23% to $207000.0 in 2025.
  • Per Business Quant, the three most recent readings for HBIO's Capital Expenditures are $207000.0 (Q3 2025), $89000.0 (Q2 2025), and $513000.0 (Q1 2025).